Skip Navigation


Annals of Oncology Advance Access originally published online on October 16, 2006
Annals of Oncology 2007 18(2):393; doi:10.1093/annonc/mdl351
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/2/393    most recent
mdl351v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Souberbielle, B
Right arrow Articles by McCloskey, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Souberbielle, B
Right arrow Articles by McCloskey, E
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

letters to the editor

The cost-effectiveness of bisphosphonates in metastatic breast cancer: letter to the editor in response to Botteman et al. 2006

The first 10% of the full text of this article appears below.

We agree with the main conclusion of the recent paper by Botteman et al. [1] entitled ‘the cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases’ that bisphosphonate use in patients with breast cancer is cost-effective. However, we consider that the paper contains key methodological . . . [Full Text of this Article]

B Souberbielle1,*, R Williams2 and E McCloskey3

1 Senior Medical Advisor
2 Medical Information Officer, Schering Health Care Ltd, The Brow, Burgess Hill, West Sussex RHI5 9NE
3 WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX

* (E-mail: bsouberbielle@schering.co.uk)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al.
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Ann. Onc., March 1, 2008; 19(3): 420 - 432.
[Abstract] [Full Text] [PDF]